Kidney BAN Costs Countless Lives: Outdated Morality?

A growing group of economists now argue that America’s ban on kidney sales is costing thousands of lives every year in the name of an outdated sense of “repugnance.”

Story Snapshot

Economists say a tightly regulated kidney market could wipe out transplant waiting lists and save thousands of Americans annually.
Federal law still bans paying for organs, grounded in claims that markets “undermine dignity” and are morally “repugnant.”
Evidence from Iran’s regulated system and U.S. policy studies suggests compensation can expand supply while limiting exploitation.
Conservatives now face a core question: should free citizens be barred from saving lives with their own bodies because elites find it offensive?

The Life‑or‑Death Cost of America’s Ban on Kidney Sales

Pro‑market economists and legal scholars have been blunt: legalizing a carefully regulated market for kidneys would increase supply, slash waiting lists, and save thousands of lives.^[1]^[2] In the United States, current law allows only donation, not payment, and the number of transplants falls far short of the need.^[2]^[4] Patients can wait close to a decade, and many die before a kidney becomes available.^[2] Supporters argue that this is not fate or bad luck; it is the predictable result of a government‑imposed price of zero.

Free‑market advocates frame this as a basic issue of liberty: if two informed adults want to enter a voluntary, medically supervised agreement that saves one life and compensates the other, why should Washington forbid it?^[1] They note that we already allow compensated risk in military service, dangerous industrial jobs, and medical trials. In their view, blocking kidney sales while tolerating those activities exposes a double standard driven more by moral discomfort than by consistent concern for human dignity or safety.^[2]

https://twitter.com/irishpatriot91/status/2035558312209453425

What Economists Mean by “Repugnant Markets”

Nobel‑winning economist Alvin Roth describes kidney sales as a classic “repugnant market,” meaning a voluntary exchange that many people want to prohibit because it feels morally offensive, even when it creates large benefits. Organ payment is one of his central examples: federal law bans compensation, and many medical institutions oppose it, despite economic models showing large gains from trade. The “repugnance” label matters politically because it gives prohibitionists a powerful vocabulary to shut down debate before the empirical evidence is even considered.

Ethicists who defend the ban argue that letting people sell kidneys “undermines the seller’s dignity” by treating the body like a spare‑parts store.^[5] They worry especially about poorer Americans who might feel financial pressure to sell, and about the risk that markets could crowd out altruistic donation. However, even pro‑ban scholars admit these are largely theoretical worries: there is little direct empirical evidence that a properly regulated system would reduce total donations or cause lasting dignity harm.^[5] Meanwhile, real people continue to die under the status quo, a cost that critics say is too often treated as abstract.

Evidence from Real‑World Experiments and Policy Proposals

Because federal law blocks direct experimentation, almost all hard data comes from abroad or from “market‑like” mechanisms that avoid cash payments. Iran operates the only national, legal kidney market, using fixed, government‑regulated payments and charitable support so that recipients, rich or poor, have equal access to transplants.^[2] Reports indicate that Iran eliminated its kidney waiting list and reduced black‑market abuse compared with nearby countries where the trade is purely illegal.^[2] The system is imperfect, but it proves that prohibition is not the only model on the table.^[2]

In the United States, researchers highlight kidney‑exchange programs, where donors who are incompatible with their loved one are matched with other pairs, as proof that economic design can dramatically increase transplants without direct cash sales.^[3] Yet even advocates of exchange recognize that exchanges alone cannot close the gap between supply and demand. Some legal scholars have proposed a regulated payment system with price caps, strict medical screening, mandatory counseling, and long‑term follow‑up care, financed in part by the savings from taking patients off lifelong dialysis.^[1]^[4] One study estimates that paying donors around $45,000 could eliminate the kidney waiting list and save taxpayers billions annually.^[2]

Liberty, Exploitation, and What Conservatives Should Demand

Opponents of kidney markets warn about exploitation and point to “transplant tourism” and underground markets in places like Pakistan and the Philippines, where the poor can be abused.^[2] Yet those abuses occur under prohibition, not legalization: they are the black‑market byproduct of desperate demand colliding with legal bans.^[2] Some economists argue that a transparent, regulated domestic market would undercut criminal brokers, set minimum standards for safety and compensation, and give donors legal recourse. In other words, it would replace exploitation in the shadows with accountable, rule‑bound exchange.

For conservatives, the core tension is familiar. On one side sits an entrenched regulatory regime justified by vague appeals to “repugnance” and paternalistic claims that the state must protect adults from choices it finds distasteful.^[5] On the other side is a freedom‑oriented approach that trusts citizens, under firm rules and full information, to decide what to do with their own bodies if it means saving a fellow American’s life.^[1] With waiting lists long and people dying, many on the right are asking whether moral discomfort is enough reason to keep that freedom illegal.